Endovia Health Sciences (EDVA) Net Cash Flow Growth (3y) (2015 - 2026)
Powered by 
Analysis
Endovia Health Sciences (EDVA) Net Cash Flow Growth (3y) (2015 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | NCF Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 141.50 Bn | 133.65 Bn | 2.84 Bn | -8.34% |
| 2 | Regeneron Pharmaceuticals | 86.53 Bn | 78.54 Bn | 3.93 Bn | 36.60% |
| 3 | Argenx Se | 65.05 Bn | 59.86 Bn | 1.37 Bn | - |
| 4 | Moderna | 57.11 Bn | 51.98 Bn | 52.00 Mn | -35.85% |
| 5 | Revolution Medicines | 44.71 Bn | 44.71 Bn | - | - |
| 6 | BeOne Medicines | 40.40 Bn | 35.31 Bn | 1.53 Bn | 106.37% |
| 7 | Alnylam Pharmaceuticals | 35.36 Bn | 32.05 Bn | 992.69 Mn | 67.39% |
| 8 | Royalty Pharma | 28.16 Bn | 27.32 Bn | - | 4.55% |
| 9 | Insmed | 27.40 Bn | 26.24 Bn | 358.27 Mn | 52.78% |
| 10 | Endovia Health Sciences | 801,166.21 | 558,464.21 | - | 27.08% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 27.08% |
| Mar 31, 2026 | 27.11% |
| Dec 31, 2025 | -26.14% |
| Sep 30, 2025 | 28.61% |
| Jun 30, 2025 | 26.74% |
| Mar 31, 2025 | -26.26% |
| Dec 31, 2024 | 27.35% |
| Sep 30, 2024 | 27.96% |
| Jun 30, 2024 | -26.00% |
| Mar 31, 2024 | -33.96% |
| Dec 31, 2023 | 51.15% |
| Sep 30, 2023 | -49.11% |
| Jun 30, 2023 | -26.75% |
| Mar 31, 2023 | -81.27% |
| Dec 31, 2022 | 435.38% |
| Sep 30, 2022 | -245.02% |
| Jun 30, 2022 | -170.36% |
| Mar 31, 2022 | 101.40% |
| Dec 31, 2021 | -529.40% |
| Sep 30, 2021 | -590.30% |